[41701 Search Results


rbd  (Cell Signaling Technology Inc)
91
Cell Signaling Technology Inc rbd
A , Box plots showing the <t>anti-SARS-CoV-2</t> <t>IgA,</t> IgM and IgG antibody proportions in serum samples from control, infected and contact along with B , Serum cytokine levels in pg/ml (Eotaxin, G-CSF, IL-7, MIF and MIP 1-□) determined by bio plex. C , The area under the receiver-operating characteristic (ROC) curve of the cytokines having more than 0.8 AUC. D , Box plot depicting the percent inhibition of neutralizing antibodies in an in -vitro spike <t>RBD-ACE2</t> interaction based Surrogate Virus Neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test, p-values are written against respective comparisons. Where, n = number of individuals, IgA-Immunoglobulin A, IgM-Immunoglobulin M and IgG-Immunoglobulin G, control (n-14), infected (n-23, Symptomatic n-10 and Asymptomatic n-13) and contact (n-24).
Rbd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rbd/product/Cell Signaling Technology Inc
Average 91 stars, based on 1 article reviews
rbd - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
epac1 siepac1  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology epac1 siepac1
(A) Intracellular levels of cAMP upon stimulation with M-CSF and RANKL in the presence or absence of cilostazol (30 μM) for 24 h were determined using an ELISA for cAMP. Intracellular cAMP was increased after 6 h exposure to M-CSF and RANKL. *, p <0.05; ***, p <0.001 compared with 0 h. ## , p <0.01; ### , p <0.001 compared with vehicle (V)-treated cells. (B, F) BMM (2 x 10 4 cells/well) were transfected with siPKAα, <t>siEpac1</t> or scRNA. Down-regulation of PKA, <t>Epac1</t> by siRNA was confirmed by RT-PCR and qPCR. ***, p <0.001 compared with scRNA. After transfection with each siRNA, cells were treated with cilostazol and stimulated with RANKL. TRAP-positive MNCs were counted after 72 h. (B) and ROS levels were measured after 48 h (F). *, p <0.05; ***, P <0.001 compared with V of scRNA-transfected cells. ## , p <0.01; ### , p <0.001 compared with V of each siRNA-transfected cells. Numbers above the histograms are ratios of the number of MNC (B) or ROS-positive cells (F) in the presence of cilostazol to in its absence. (C) BMM were stimulated with M-CSF and RANKL along with H-89 (1 μM) in the presence or absence of cilostazol (30 μM), forskolin (1 μM), or sp-cAMP (10 μM) for 3 d and TRAP-positive MNCs were measured). **, p <0.01; ***, P <0.001 compared with vehicle. ### , p <0.001 compared with V of H-89-treated cells. Numbers above the histogram are ratios of the number of TRAP-positive MNC in the presence of cilostazol to in its absence for each group. (D) Intracellular levels of ROS upon stimulation with RANKL in the presence or absence of cilostazol (30 μM) for 48 h were determined using H 2 DCFDA. ROS levels were quantified by flow cytometry. (E) BMMs were transfected with sip47 phox or scRNA. Down-regulation of p47 phox by siRNA was confirmed by RT-PCR and qPCR. **, p <0.01 compared with scRNA. After transfection with siRNA, cells were treated with cilostazol and stimulated with RANKL for 72 h and TRAP-positive MNCs counted. ***, P <0.001 compared with V of scRNA-transfected cells. There was no significant difference between V and cilostazol after transfection of sip47 phox . Numbers of OCs were counted blind by quantification of TRAP-positive MNC/ each well using an eyepiece graticule at a magnification of Χ100. Results were expressed as means ± SEM of 3–6 cultures per variable. Similar results were obtained in three independent experiments.
Epac1 Siepac1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/epac1 siepac1/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
epac1 siepac1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cassette 41701  (AS ONE Corporation)
90
AS ONE Corporation cassette 41701
(A) Intracellular levels of cAMP upon stimulation with M-CSF and RANKL in the presence or absence of cilostazol (30 μM) for 24 h were determined using an ELISA for cAMP. Intracellular cAMP was increased after 6 h exposure to M-CSF and RANKL. *, p <0.05; ***, p <0.001 compared with 0 h. ## , p <0.01; ### , p <0.001 compared with vehicle (V)-treated cells. (B, F) BMM (2 x 10 4 cells/well) were transfected with siPKAα, <t>siEpac1</t> or scRNA. Down-regulation of PKA, <t>Epac1</t> by siRNA was confirmed by RT-PCR and qPCR. ***, p <0.001 compared with scRNA. After transfection with each siRNA, cells were treated with cilostazol and stimulated with RANKL. TRAP-positive MNCs were counted after 72 h. (B) and ROS levels were measured after 48 h (F). *, p <0.05; ***, P <0.001 compared with V of scRNA-transfected cells. ## , p <0.01; ### , p <0.001 compared with V of each siRNA-transfected cells. Numbers above the histograms are ratios of the number of MNC (B) or ROS-positive cells (F) in the presence of cilostazol to in its absence. (C) BMM were stimulated with M-CSF and RANKL along with H-89 (1 μM) in the presence or absence of cilostazol (30 μM), forskolin (1 μM), or sp-cAMP (10 μM) for 3 d and TRAP-positive MNCs were measured). **, p <0.01; ***, P <0.001 compared with vehicle. ### , p <0.001 compared with V of H-89-treated cells. Numbers above the histogram are ratios of the number of TRAP-positive MNC in the presence of cilostazol to in its absence for each group. (D) Intracellular levels of ROS upon stimulation with RANKL in the presence or absence of cilostazol (30 μM) for 48 h were determined using H 2 DCFDA. ROS levels were quantified by flow cytometry. (E) BMMs were transfected with sip47 phox or scRNA. Down-regulation of p47 phox by siRNA was confirmed by RT-PCR and qPCR. **, p <0.01 compared with scRNA. After transfection with siRNA, cells were treated with cilostazol and stimulated with RANKL for 72 h and TRAP-positive MNCs counted. ***, P <0.001 compared with V of scRNA-transfected cells. There was no significant difference between V and cilostazol after transfection of sip47 phox . Numbers of OCs were counted blind by quantification of TRAP-positive MNC/ each well using an eyepiece graticule at a magnification of Χ100. Results were expressed as means ± SEM of 3–6 cultures per variable. Similar results were obtained in three independent experiments.
Cassette 41701, supplied by AS ONE Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cassette 41701/product/AS ONE Corporation
Average 90 stars, based on 1 article reviews
cassette 41701 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


A , Box plots showing the anti-SARS-CoV-2 IgA, IgM and IgG antibody proportions in serum samples from control, infected and contact along with B , Serum cytokine levels in pg/ml (Eotaxin, G-CSF, IL-7, MIF and MIP 1-□) determined by bio plex. C , The area under the receiver-operating characteristic (ROC) curve of the cytokines having more than 0.8 AUC. D , Box plot depicting the percent inhibition of neutralizing antibodies in an in -vitro spike RBD-ACE2 interaction based Surrogate Virus Neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test, p-values are written against respective comparisons. Where, n = number of individuals, IgA-Immunoglobulin A, IgM-Immunoglobulin M and IgG-Immunoglobulin G, control (n-14), infected (n-23, Symptomatic n-10 and Asymptomatic n-13) and contact (n-24).

Journal: medRxiv

Article Title: SARS-CoV-2 specific immune-signature in direct contacts of COVID-19 cases protect them from contracting disease: A Retrospective Study

doi: 10.1101/2021.03.11.21253367

Figure Lengend Snippet: A , Box plots showing the anti-SARS-CoV-2 IgA, IgM and IgG antibody proportions in serum samples from control, infected and contact along with B , Serum cytokine levels in pg/ml (Eotaxin, G-CSF, IL-7, MIF and MIP 1-□) determined by bio plex. C , The area under the receiver-operating characteristic (ROC) curve of the cytokines having more than 0.8 AUC. D , Box plot depicting the percent inhibition of neutralizing antibodies in an in -vitro spike RBD-ACE2 interaction based Surrogate Virus Neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test, p-values are written against respective comparisons. Where, n = number of individuals, IgA-Immunoglobulin A, IgM-Immunoglobulin M and IgG-Immunoglobulin G, control (n-14), infected (n-23, Symptomatic n-10 and Asymptomatic n-13) and contact (n-24).

Article Snippet: For IgA and IgM quantification, RBD (SARS-CoV-2 spike RBD recombinant protein, mFc-Tag, CST # 41701S) antigen at a concentration of 200ng/well was coated in a 96-well high binding micro titre plate (HIMEDIA-EP1) in 1x TBS pH-7.4 for 2h at 37□.

Techniques: Infection, Inhibition, In Vitro, Neutralization

(A) Intracellular levels of cAMP upon stimulation with M-CSF and RANKL in the presence or absence of cilostazol (30 μM) for 24 h were determined using an ELISA for cAMP. Intracellular cAMP was increased after 6 h exposure to M-CSF and RANKL. *, p <0.05; ***, p <0.001 compared with 0 h. ## , p <0.01; ### , p <0.001 compared with vehicle (V)-treated cells. (B, F) BMM (2 x 10 4 cells/well) were transfected with siPKAα, siEpac1 or scRNA. Down-regulation of PKA, Epac1 by siRNA was confirmed by RT-PCR and qPCR. ***, p <0.001 compared with scRNA. After transfection with each siRNA, cells were treated with cilostazol and stimulated with RANKL. TRAP-positive MNCs were counted after 72 h. (B) and ROS levels were measured after 48 h (F). *, p <0.05; ***, P <0.001 compared with V of scRNA-transfected cells. ## , p <0.01; ### , p <0.001 compared with V of each siRNA-transfected cells. Numbers above the histograms are ratios of the number of MNC (B) or ROS-positive cells (F) in the presence of cilostazol to in its absence. (C) BMM were stimulated with M-CSF and RANKL along with H-89 (1 μM) in the presence or absence of cilostazol (30 μM), forskolin (1 μM), or sp-cAMP (10 μM) for 3 d and TRAP-positive MNCs were measured). **, p <0.01; ***, P <0.001 compared with vehicle. ### , p <0.001 compared with V of H-89-treated cells. Numbers above the histogram are ratios of the number of TRAP-positive MNC in the presence of cilostazol to in its absence for each group. (D) Intracellular levels of ROS upon stimulation with RANKL in the presence or absence of cilostazol (30 μM) for 48 h were determined using H 2 DCFDA. ROS levels were quantified by flow cytometry. (E) BMMs were transfected with sip47 phox or scRNA. Down-regulation of p47 phox by siRNA was confirmed by RT-PCR and qPCR. **, p <0.01 compared with scRNA. After transfection with siRNA, cells were treated with cilostazol and stimulated with RANKL for 72 h and TRAP-positive MNCs counted. ***, P <0.001 compared with V of scRNA-transfected cells. There was no significant difference between V and cilostazol after transfection of sip47 phox . Numbers of OCs were counted blind by quantification of TRAP-positive MNC/ each well using an eyepiece graticule at a magnification of Χ100. Results were expressed as means ± SEM of 3–6 cultures per variable. Similar results were obtained in three independent experiments.

Journal: PLoS ONE

Article Title: Cilostazol Attenuates Ovariectomy-Induced Bone Loss by Inhibiting Osteoclastogenesis

doi: 10.1371/journal.pone.0124869

Figure Lengend Snippet: (A) Intracellular levels of cAMP upon stimulation with M-CSF and RANKL in the presence or absence of cilostazol (30 μM) for 24 h were determined using an ELISA for cAMP. Intracellular cAMP was increased after 6 h exposure to M-CSF and RANKL. *, p <0.05; ***, p <0.001 compared with 0 h. ## , p <0.01; ### , p <0.001 compared with vehicle (V)-treated cells. (B, F) BMM (2 x 10 4 cells/well) were transfected with siPKAα, siEpac1 or scRNA. Down-regulation of PKA, Epac1 by siRNA was confirmed by RT-PCR and qPCR. ***, p <0.001 compared with scRNA. After transfection with each siRNA, cells were treated with cilostazol and stimulated with RANKL. TRAP-positive MNCs were counted after 72 h. (B) and ROS levels were measured after 48 h (F). *, p <0.05; ***, P <0.001 compared with V of scRNA-transfected cells. ## , p <0.01; ### , p <0.001 compared with V of each siRNA-transfected cells. Numbers above the histograms are ratios of the number of MNC (B) or ROS-positive cells (F) in the presence of cilostazol to in its absence. (C) BMM were stimulated with M-CSF and RANKL along with H-89 (1 μM) in the presence or absence of cilostazol (30 μM), forskolin (1 μM), or sp-cAMP (10 μM) for 3 d and TRAP-positive MNCs were measured). **, p <0.01; ***, P <0.001 compared with vehicle. ### , p <0.001 compared with V of H-89-treated cells. Numbers above the histogram are ratios of the number of TRAP-positive MNC in the presence of cilostazol to in its absence for each group. (D) Intracellular levels of ROS upon stimulation with RANKL in the presence or absence of cilostazol (30 μM) for 48 h were determined using H 2 DCFDA. ROS levels were quantified by flow cytometry. (E) BMMs were transfected with sip47 phox or scRNA. Down-regulation of p47 phox by siRNA was confirmed by RT-PCR and qPCR. **, p <0.01 compared with scRNA. After transfection with siRNA, cells were treated with cilostazol and stimulated with RANKL for 72 h and TRAP-positive MNCs counted. ***, P <0.001 compared with V of scRNA-transfected cells. There was no significant difference between V and cilostazol after transfection of sip47 phox . Numbers of OCs were counted blind by quantification of TRAP-positive MNC/ each well using an eyepiece graticule at a magnification of Χ100. Results were expressed as means ± SEM of 3–6 cultures per variable. Similar results were obtained in three independent experiments.

Article Snippet: The BMM were transfected with small interfering RNA (siRNA) against Epac1 (siEpac1) (sc-41701; Santa Cruz Biotechnology), protein kinase A catalytic subunit α (siPKAα) (sc-36241), p47 phox (sip47 phox ) (sc-36157) or scrambled siRNA (scRNA) (Santa Cruz, Santa Cruz, CA) using Lipofectamine RNAiMAX (Invitrogen), and further analyzed.

Techniques: Enzyme-linked Immunosorbent Assay, Transfection, Reverse Transcription Polymerase Chain Reaction, Flow Cytometry